Join
Live feed
·
PRReleasevia Quantisnow
Rhythm Pharmaceuticals Inc. logo

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

ByQuantisnow·Wall Street's wire, on your screen.
RYTM· Rhythm Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RYTM (Rhythm Pharmaceuticals Inc.) and more on Quantisnow.